Ondansetron Viatris

Ondansetron, the active ingredient in Ondansetron Viatris, is a 5‑HT3 receptor antagonist presented as an intravenous solution for injection use. It prevents nausea and vomiting associated with chemotherapy, postoperative recovery, and radiation therapy in adult and pediatric patients.

GNH USA supplies Ondansetron Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Ondansetron is a 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: reduces the incidence and severity of nausea and vomiting in patients receiving emetogenic chemotherapy. - Postoperative nausea and vomiting: prevents nausea and vomiting after surgical procedures. - Radiation‑induced nausea and vomiting: mitigates nausea and vomiting associated with radiotherapy.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Dizziness: sensation of light‑headedness. - Fatigue: general tiredness. - Injection site reactions: pain, erythema, or phlebitis at the IV site.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmia. - Severe allergic reactions: anaphylaxis, rash, or angioedema. - Serotonin syndrome: agitation, hyperthermia, or neuromuscular abnormalities when combined with serotonergic agents. - Cardiac arrhythmias: ventricular tachycardia or fibrillation. - Severe hypotension: sudden drop in blood pressure. - Hepatic dysfunction: elevated liver enzymes or jaundice.

Before initiating therapy, consider the following precautions.

- Assess cardiac risk: evaluate QT interval and correct electrolyte abnormalities. - Avoid in patients with known hypersensitivity to ondansetron or other serotonin antagonists. - Use caution in hepatic impairment: dose adjustment may be required. - Monitor electrolytes: especially potassium and magnesium levels. - Store at controlled room temperature: keep in the original container, protect from light and moisture.

Ondansetron may interact with several medicines; review the following.

Major Interactions (Avoid): - Concurrent use with other QT‑prolonging drugs: increased risk of cardiac arrhythmia. - Combination with apomorphine: can cause severe hypotension and loss of consciousness. - Co‑administration with carbamazepine: may reduce ondansetron efficacy.

Moderate Interactions (Monitor Closely): - Use with serotonergic agents (e.g., SSRIs, MAO inhibitors): potential for serotonin syndrome. - Interaction with dexamethasone: may enhance anti‑emetic effect. - Concurrent use with CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels of ondansetron.